DarioHealth Corp (DRIO)
NASDAQ:DRIO
Want to see DRIO full AI Analyst Report?
DRIO Stock Chart & Stats
$11.72
-$0.63(-41.18%)
At close: 4:00 PM EST
$11.72
-$0.63(-41.18%)
Day’s Range― - ―
52-Week Range$5.94 - $17.74
Previous CloseN/A
Volume780.96K
Average Volume (3M)33.32K
Market Cap
$57.48M
Enterprise Value$69.03M
Total Cash (Recent Filing)$20.26M
Total Debt (Recent Filing)$31.82M
Price to Earnings (P/E)―
Beta0.54
Next Earnings
Aug 17, 2026EPS Estimate
-1.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.25
Shares Outstanding7,312,398
10 Day Avg. Volume41,359
30 Day Avg. Volume33,324
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)8.32
Price to Sales (P/S)25.26
P/FCF Ratio-21.65
Enterprise Value/Market Cap1.20
Enterprise Value/Revenue3.26
Enterprise Value/Gross Profit5.76
Enterprise Value/Ebitda-1.96
Forecast
1Y Price Target
$10.50Price Target Upside-10.41% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-4.79
Revenue Forecast (FY)$26.24M
Bulls Say, Bears Say
Bulls Say
Client AcquisitionThe company noted two new major health plan clients, with one scheduled to launch in the second half of 2025, bringing their total clients signed year-to-date to 21.
Financial ManagementEncouraged by management's ability to lower expenses and continue to sign meaningful new customer.
Growth OpportunitiesManagement quantified their pipeline at $53 million, with $5 million being in an advanced stage, indicating potential growth opportunities.
Bears Say
Contract RenewalA significant contract expiration contributed to the revenue miss and is pending renewal.
Guidance AdjustmentDarioHealth subsequently cut its breakeven cash flow guidance from the end of 2025 to the end of 2026 or early 2027.
Revenue ChallengesThe 2Q headline numbers were disappointing, with revenue and EBITDA coming in substantially below estimates.
DarioHealth News
DRIO FAQ
What was DarioHealth Corp’s price range in the past 12 months?
DarioHealth Corp lowest stock price was $5.93 and its highest was $17.74 in the past 12 months.
What is DarioHealth Corp’s market cap?
DarioHealth Corp’s market cap is $57.48M.
When is DarioHealth Corp’s upcoming earnings report date?
DarioHealth Corp’s upcoming earnings report date is Aug 17, 2026 which is in 85 days.
How were DarioHealth Corp’s earnings last quarter?
DarioHealth Corp released its earnings results on May 13, 2026. The company reported -$1.25 earnings per share for the quarter, beating the consensus estimate of -$1.48 by $0.23.
Is DarioHealth Corp overvalued?
According to Wall Street analysts DarioHealth Corp’s price is currently Overvalued.
Does DarioHealth Corp pay dividends?
DarioHealth Corp does not currently pay dividends.
What is DarioHealth Corp’s EPS estimate?
DarioHealth Corp’s EPS estimate is -1.22.
How many shares outstanding does DarioHealth Corp have?
DarioHealth Corp has 7,312,398 shares outstanding.
What happened to DarioHealth Corp’s price movement after its last earnings report?
DarioHealth Corp reported an EPS of -$1.25 in its last earnings report, beating expectations of -$1.48. Following the earnings report the stock price went down -6.682%.
Which hedge fund is a major shareholder of DarioHealth Corp?
Currently, no hedge funds are holding shares in DRIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
DarioHealth Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-23.65%
12-Months-Change
Fundamentals
Return on Equity
93.18%
Trailing 12-Months
Asset Growth
-10.66%
Trailing 12-Months
Company Description
DarioHealth Corp
DarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. The company offers Dario's metabolic solutions to address metabolic health needs, such as diabetes, hypertension, and weight management; Dario Musculoskeletal, which helps to prevent and treat the most common MSK conditions; Dario's behavioral health solution that optimizes access to evidence-based care; chronic condition management solutions; DarioEngage, a proprietary care management platform; and device-specific disposables test strip cartridges, lancets, and blood glucose monitoring systems. It also provides smart glucose meters; bluetooth connected blood pressure cuff; digital scales; biofeedback sensor devices; and diabetes management programs, including lifestyle changes, healthy eating, advanced tracking, and live coaching. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.
DRIO Company Deck
DRIO Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized sequential revenue growth, a materially improved cost structure, a sizeable commercial pipeline ($127M) and expanding channel distribution (targeting >175M covered lives), supported by proprietary data assets and early AI-driven engagement gains. Key positives include meaningful OpEx reductions, improving margins on core B2B2C offerings (~80% non-GAAP gross margin), a clear strategic push to participate in care- and outcomes-based revenue via partnerships, and accelerating consumer product demand. Offsetting these positives are a year-over-year revenue decline tied to deliberate removal of non-recurring pharmaceutical revenue, continued GAAP and non-GAAP operating losses, dependence on the timing of large partner conversions (implementation and onboarding risks), limited near-term revenue visibility and an ongoing strategic review that introduces some uncertainty. On balance, management presented measurable operational improvements and a clear path toward scaled, higher-margin channel revenue, while acknowledging conversion and timing risks that remain to be resolved.View all DRIO earnings summariesDRIO Stock 12 Month Forecast
Average Price Target
$10.50
▼(-10.41% Downside)
Technical Analysis
Ownership Overview
7.32% Insiders
1.59% Mutual Funds
8.36% Other Institutional Investors
81.82% Public Companies and
Individual Investors